Skip to main content
. 2006 Oct 13;399(Pt 3):493–501. doi: 10.1042/BJ20051628

Figure 5. Effect of Raf inhibition on the activation of ERK1/2 in ARVM.

Figure 5

(A) Western blot of phosphorylated ERK1/2 (pERK1/2) in control cells or following 5 min exposure to 100 μM phenylephrine in the absence (vehicle) or presence of 3 μM GW 5074, and quantitative data from four separate experiments. Data are expressed as fold phosphorylation normalized to vehicle control. (B) Western blot of phosphorylated ERK1/2 (pERK1/2) in control cells or following sustained intracellular acidosis in the absence (vehicle) or presence of 3 μM GW 5074, and quantitative data from four separate experiments. Data are expressed as fold phosphorylation normalized to vehicle control. (C) Western blot of phosphorylated ERK1/2 (pERK1/2) in control cells or following sustained intracellular acidosis in the absence (vehicle) or presence of 50 μM ZM 336372, and quantitative data from four separate experiments. Data are expressed as fold phosphorylation normalized to vehicle control. *P<0.05 compared with control.